Latest News | Dr Reddy's Laboratories Launches Generic Drug in US Market
Get latest articles and stories on Latest News at LatestLY. Dr Reddy's Laboratories on Wednesday said it has launched vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
New Delhi, Feb 9 (PTI) Dr Reddy's Laboratories on Wednesday said it has launched vasopressin injection, which is used to control frequent urination, increased thirst, and loss of water caused by diabetes, in the American market.
The company has launched the product, a generic version of Par Pharmaceuticals' Vasostrict, in the US market after getting approval from the US Food and Drug Administration (USFDA).
Also Read | RBI Likely To Keep Key Rates Unchanged in Its First MPC Meet After Budget 2022-23.
“We are pleased to provide this important authorised generic product to patients, especially in these difficult times of COVID-19,” Dr Reddy's Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.
According to IQVIA Health, Vasostrict brand had sales of around USD 878.5 million for the most recent twelve months ending December 2021.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)